Ingvild Haaland

461 total citations
23 papers, 366 citations indexed

About

Ingvild Haaland is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Emergency Medical Services. According to data from OpenAlex, Ingvild Haaland has authored 23 papers receiving a total of 366 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 11 papers in Pulmonary and Respiratory Medicine and 5 papers in Emergency Medical Services. Recurrent topics in Ingvild Haaland's work include Chronic Obstructive Pulmonary Disease (COPD) Research (7 papers), Gut microbiota and health (7 papers) and Pediatric health and respiratory diseases (5 papers). Ingvild Haaland is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (7 papers), Gut microbiota and health (7 papers) and Pediatric health and respiratory diseases (5 papers). Ingvild Haaland collaborates with scholars based in Norway, United Kingdom and Netherlands. Ingvild Haaland's co-authors include Bjørn Tore Gjertsen, Tomas Eagan, Øyvind Bruserud, Øystein Bruserud, Stian Knappskog, Emmet McCormack, Nina Ånensen, Harald G. Wiker, Werner Van Belle and Rune Nielsen and has published in prestigious journals such as PLoS ONE, Oncogene and European Respiratory Journal.

In The Last Decade

Ingvild Haaland

22 papers receiving 358 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ingvild Haaland Norway 12 254 92 66 65 42 23 366
Debalina Sarkar India 7 101 0.4× 90 1.0× 29 0.4× 23 0.4× 20 0.5× 12 341
K. Taniguchi Japan 13 123 0.5× 150 1.6× 24 0.4× 59 0.9× 63 1.5× 35 620
Steven R. Rousey United States 10 132 0.5× 140 1.5× 41 0.6× 118 1.8× 105 2.5× 20 391
Rena J. May United States 10 198 0.8× 141 1.5× 24 0.4× 40 0.6× 49 1.2× 13 458
Artur Mitterer Austria 13 181 0.7× 31 0.3× 387 5.9× 36 0.6× 28 0.7× 35 632
Beth C. Holbrook United States 15 223 0.9× 62 0.7× 10 0.2× 27 0.4× 242 5.8× 32 723
Marijana Ručević United States 14 249 1.0× 69 0.8× 34 0.5× 21 0.3× 45 1.1× 23 578
Peeter Padrik Estonia 15 161 0.6× 161 1.8× 39 0.6× 67 1.0× 42 1.0× 43 518
Armando C. Rodriguez United States 9 547 2.2× 84 0.9× 40 0.6× 15 0.2× 71 1.7× 9 796
Sylvie Cochet France 13 252 1.0× 26 0.3× 120 1.8× 46 0.7× 18 0.4× 36 531

Countries citing papers authored by Ingvild Haaland

Since Specialization
Citations

This map shows the geographic impact of Ingvild Haaland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ingvild Haaland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ingvild Haaland more than expected).

Fields of papers citing papers by Ingvild Haaland

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ingvild Haaland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ingvild Haaland. The network helps show where Ingvild Haaland may publish in the future.

Co-authorship network of co-authors of Ingvild Haaland

This figure shows the co-authorship network connecting the top 25 collaborators of Ingvild Haaland. A scholar is included among the top collaborators of Ingvild Haaland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ingvild Haaland. Ingvild Haaland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Eagan, Tomas, Rune Nielsen, Ingvild Haaland, et al.. (2025). Inflammatory cells and remodeling in bronchial biopsies from COPD patients and controls. PLoS ONE. 20(6). e0326267–e0326267.
2.
Lehmann, Sverre, et al.. (2022). The lower airways microbiome and antimicrobial peptides in idiopathic pulmonary fibrosis differ from chronic obstructive pulmonary disease. PLoS ONE. 17(1). e0262082–e0262082. 7 indexed citations
3.
Eagan, Tomas, et al.. (2021). Exploring protocol bias in airway microbiome studies: one versus two PCR steps and 16S rRNA gene region V3 V4 versus V4. BMC Genomics. 22(1). 3–3. 20 indexed citations
4.
Haaland, Ingvild, Håkon Reikvam, André Sulen, et al.. (2021). p53 Protein Isoform Profiles in AML: Correlation with Distinct Differentiation Stages and Response to Epigenetic Differentiation Therapy. Cells. 10(4). 833–833. 5 indexed citations
5.
Nielsen, Rune, Yaxin Xue, Inge Jonassen, et al.. (2021). Repeated bronchoscopy in health and obstructive lung disease: is the airway microbiome stable?. BMC Pulmonary Medicine. 21(1). 342–342. 7 indexed citations
6.
Eagan, Tomas, Ingvild Haaland, Gunnar Reksten Husebø, et al.. (2021). The pulmonary mycobiome—A study of subjects with and without chronic obstructive pulmonary disease. PLoS ONE. 16(4). e0248967–e0248967. 21 indexed citations
7.
Grønseth, Rune, et al.. (2017). The microbiome of COPD in protected, bronchoscopic airway samples. PA378–PA378. 1 indexed citations
8.
Grønseth, Rune, Harald G. Wiker, Yaxin Xue, et al.. (2017). Protected sampling is preferable in bronchoscopic studies of the airway microbiome. ERJ Open Research. 3(3). 19–2017. 29 indexed citations
9.
Lehmann, Sverre, et al.. (2017). A pilot study of hot-wire, ultrasonic and wedge-bellows spirometer inter- and intra-variability. BMC Research Notes. 10(1). 497–497. 7 indexed citations
10.
Eagan, Tomas, Harald G. Wiker, Ingvild Haaland, et al.. (2016). Laboratory contamination in airway microbiome studies. PA3984–PA3984. 3 indexed citations
11.
Haaland, Ingvild, et al.. (2014). Interleukin-18 levels in induced sputum of stable and exacerbated COPD patients. European Respiratory Journal. 44(Suppl 58). P848–P848. 1 indexed citations
12.
Eagan, Tomas, Per Bakke, Ingvild Haaland, et al.. (2014). Fever, hospitalization and healthcare utilization after research bronchoscopy. European Respiratory Journal. 44(Suppl 58). P702–P702. 1 indexed citations
13.
Haaland, Ingvild, Jill A. Opsahl, Frode S. Berven, et al.. (2014). Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia. Molecular Cancer. 13(1). 116–116. 25 indexed citations
14.
Haaland, Ingvild, et al.. (2013). cAMP signalling inhibits p53 acetylation and apoptosis via HDAC and SIRT deacetylases. International Journal of Oncology. 42(5). 1815–1821. 24 indexed citations
15.
Ånensen, Nina, Werner Van Belle, Ingvild Haaland, et al.. (2011). Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia. Oncogene. 31(12). 1533–1545. 51 indexed citations
16.
McCormack, Emmet, Ingvild Haaland, Gro Gausdal, et al.. (2011). Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia. Leukemia. 26(5). 910–917. 73 indexed citations
17.
Haaland, Ingvild, et al.. (2010). Clinical proteomics of myeloid leukemia. Genome Medicine. 2(6). 41–41. 14 indexed citations
18.
Wergeland, Line, et al.. (2007). Pre-apoptotic response to therapeutic DNA damage involves protein modulation of Mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells. Molecular Cancer. 6(1). 33–33. 17 indexed citations
19.
Belle, Werner Van, Nina Ånensen, Ingvild Haaland, et al.. (2006). Correlation analysis of two-dimensional gel electrophoretic protein patterns and biological variables. BMC Bioinformatics. 7(1). 198–198. 22 indexed citations
20.
Ånensen, Nina, et al.. (2006). Proteomics of p53 in Diagnostics and Therapy of Acute Myeloid Leukemia. Current Pharmaceutical Biotechnology. 7(3). 199–207. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Debalina Sarkar Breakdown of academic impact, for papers by K. Taniguchi Breakdown of academic impact, for papers by Steven R. Rousey Breakdown of academic impact, for papers by Rena J. May Breakdown of academic impact, for papers by Artur Mitterer Breakdown of academic impact, for papers by Beth C. Holbrook Breakdown of academic impact, for papers by Marijana Ručević Breakdown of academic impact, for papers by Peeter Padrik Breakdown of academic impact, for papers by Armando C. Rodriguez Breakdown of academic impact, for papers by Sylvie Cochet
Rankless by CCL
2026